PainReform Future Growth
Future criteria checks 0/6
PainReform is forecast to grow earnings and revenue by 19.3% and 77.9% per annum respectively while EPS is expected to grow by 36.9% per annum.
Key information
19.3%
Earnings growth rate
36.9%
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 77.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -17 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -18 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -15 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -9 | -7 | -7 | N/A |
| 9/30/2023 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2023 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2023 | N/A | -9 | -7 | -7 | N/A |
| 12/31/2022 | N/A | -9 | -6 | -6 | N/A |
| 9/30/2022 | N/A | -7 | -5 | -5 | N/A |
| 6/30/2022 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2022 | N/A | -7 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -7 | -7 | -7 | N/A |
| 9/30/2021 | N/A | -7 | -7 | -7 | N/A |
| 6/30/2021 | N/A | -5 | -6 | -6 | N/A |
| 3/31/2021 | N/A | -5 | -4 | -4 | N/A |
| 12/31/2020 | N/A | -4 | -3 | -3 | N/A |
| 9/30/2020 | N/A | -4 | -1 | -1 | N/A |
| 6/30/2020 | N/A | -4 | -1 | -1 | N/A |
| 3/31/2020 | N/A | -4 | -1 | -1 | N/A |
| 12/31/2019 | N/A | -2 | -1 | -1 | N/A |
| 9/30/2019 | N/A | -2 | -1 | -1 | N/A |
| 6/30/2019 | N/A | -2 | 0 | 0 | N/A |
| 3/31/2019 | N/A | -2 | -1 | -1 | N/A |
| 12/31/2018 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRFX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRFX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRFX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRFX is forecast to have no revenue next year.
High Growth Revenue: PRFX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRFX's Return on Equity is forecast to be high in 3 years time